94 death in after vaccinated for influenza: more than 80% are elderly, the government has not decided to stopped yet!
November 5 According to Yonhap News Agency, the Korean Disease Management Agency reported that as of 0:00 on November 5, 94 people in South Korea had died after being vaccinated with influenza. After investigation, it was determined that there is no direct causal relationship between 87 deaths and vaccination, and the remaining 7 cases are still undergoing epidemiological investigation. Currently, the South Korean government has not stopped influenza vaccination.
Since a 17-year-old boy in Incheon died two days after being vaccinated on October 16th, there have been cases of death after being vaccinated in various parts of Korea. At present, more than 80% (83.0%) of the 94 dead are elderly people over 70 years old, all over Korea.
On October 27, South Korean President Moon Jae-in responded to the incident for the first time, saying that he hoped that the public would trust the conclusions of the health department and experts, and called for continued expansion of the scope of influenza vaccination. He said that through the autopsy and comprehensive judgment of the death cases, it has been determined that there is no direct causal relationship between the death cases after influenza vaccination and vaccination.
Moon Jae-in also said that in order to prevent influenza and the simultaneous infection and spread of influenza and new crowns, it is necessary to continue to expand the scope of influenza vaccination. “I hope that I will not miss the timely vaccination because of being too uneasy, and accidentally contract the high-fatal influenza flu, causing greater danger.”
It is reported that the influenza vaccine used in the free vaccination program in South Korea is supplied by five pharmaceutical companies, namely the local GC Pharmaceutical Company, SK Biotech, Yiyang Pharmaceutical Company, France’s Sanofi Group, and British GlaxoSmithKline. Distributors include South Korea’s LG Chemical Company and Boryeong Pharmaceutical Company.
The Korean vaccine incident has also aroused the attention of the international community. Late at night on October 25, Singapore’s health department issued a statement saying that in view of South Korea’s reports of multiple deaths after influenza vaccination, although Singapore has not reported deaths after vaccination, Singapore has suspended the use of the two influenza vaccines adopted in South Korea for precautions. The vaccines are SKYCellflu Quadrivalent and VaxigripTetra.
